Medincell Promotes Grace Kim Chief Strategy Officer U.S. Finance

Medincell, a clinical-stage pharmaceutical company in long-acting injectable therapies, today announced the expanded role of Dr Grace Kim, Chief Strategy Officer, U.S. Finance.

Over the past two years, Kim has played has initial and decisive role in shaping the company’s U.S. capital growth strategy and advancing cross-border initiatives.

As Medincell enters a pivotal growth phase, Kim will build on this foundation to lead and execute the next stages of the company’s U.S. capital growth strategy, driving long-term value for patients, partners, and investors.

Kim serves as Medincell’s Chief Strategy Officer, U.S. Finance, acting as an execution partner for the company’s U.S. capital strategy and global expansion.

Kim has two decades of experience in Capital Markets, Corporate Strategy, and Investment Banking. Kim previously served as Chief Strategy Officer of Molecular Templates and CEO of SNO Bio. She also leads a longstanding NY biotech advisory. 

With a $10 billion track record, Grace has driven value for over 160 companies, including BeiGene/BeOne, Biomarin, Cullinan Therapeutics, Zai Lab, Aimmune/Nestle, Immunity Bio, and Umoja Biopharma.